Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Follicular 3Leukemia 3Waldenstrom Macroglobulinemia 2Neoplasms 2Leukemia, B-Cell 2Stomach Neoplasms 1Hodgkin Disease 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Chlorambucil × Clear all
NCT00748189 2019-06-25

COMPLEMENT 1

Novartis

Phase 3 Terminated
447 enrolled 32 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01657955 2012-08-06

CLL

Shandong Lanjin Pharmaceuticals Co.,Ltd

Phase 3 Unknown
96 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡